Developing anticancer drugs in orphan molecular entities - A paradigm under construction

New England Journal of Medicine

Volumn 378, Issue 8, 2018, Pages 763-765

  André, Fabrice ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ORPHAN DRUG;

CANCER CHEMOTHERAPY; DRUG DEVELOPMENT; EDITORIAL; GENE; GENE TRANSLOCATION; GENOMICS; HUMAN; NTRK GENE; PRIORITY JOURNAL; DRUG APPROVAL; DRUG MANUFACTURE;

DRUG APPROVAL; HUMANS; ORPHAN DRUG PRODUCTION;

EID: 85042463150     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1716821     Document Type: Editorial

References (10)

1. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5:25-34.
2. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731-9.
3. Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017;28:2340-66.
4. AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov 2017;7:818-31.
5. Planchard D, Smit EF, Groen H J M, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017;18:1307-16.
6. Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med 2017;377:1409-12.
7. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:731-9.
8. Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 2011;29:1236-8.
9. FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation. Silver Spring, MD: Food and Drug Administration, June 22, 2017 (https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564331.htm).
10. Plan France Médecine Génomique 2025. French National Alliance for Life Sciences and Health (Aviesan), June 22, 2016 (https://www.aviesan. fr/en/aviesan/accueil/toute-l-actualite/plan-france-medecine-genomique-2025).